S&P 500   3,818.83
DOW   31,029.31
QQQ   283.80
S&P 500   3,818.83
DOW   31,029.31
QQQ   283.80
S&P 500   3,818.83
DOW   31,029.31
QQQ   283.80
S&P 500   3,818.83
DOW   31,029.31
QQQ   283.80

Beam Therapeutics Stock Forecast, Price & News

+0.02 (+0.05%)
(As of 06/29/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
1.26 million shs
Average Volume
1.19 million shs
Market Capitalization
$2.84 billion
P/E Ratio
Dividend Yield
Price Target
30 days | 90 days | 365 days | Advanced Chart

Receive BEAM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Beam Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

BEAM Stock Forecast (MarketRank)

Overall MarketRank

1.86 out of 5 stars

Medical Sector

732nd out of 1,432 stocks

Biological Products, Except Diagnostic Industry

116th out of 217 stocks

Analyst Opinion: 3.4Community Rank: 3.5Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.0 5 -4 -3 -2 -1 -
Beam Therapeutics logo

About Beam Therapeutics (NASDAQ:BEAM)

Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia; and BEAM-301, a liver-targeted development candidate for the treatment of patients with Glycogen Storage Disease Type Ia. It also develops therapies for alpha-1 antitrypsin deficiency; ocular diseases; and other liver, muscle, and central nervous system disorders. The company has an alliance with Boston Children's Hospital; a research and clinical trial collaboration agreement with Magenta Therapeutics, Inc.; license agreement with Sana Biotechnology, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. It also has a research collaboration agreement with Pfizer Inc. and Apellis Pharmaceuticals, Inc.; and collaboration and license agreement with Verve Therapeutics, Inc. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.

BEAM Stock News Headlines

See More Headlines

Industry, Sector and Symbol

Biological products, except diagnostic
Current Symbol
Year Founded

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Price Target and Rating

Average Stock Price Forecast
High Stock Price Forecast
Low Stock Price Forecast
Forecasted Upside/Downside
Consensus Rating
Moderate Buy
Rating Score (0-4)
Research Coverage
7 Analysts


Net Income
$-370.64 million
Net Margins
Pretax Margin


Sales & Book Value

Annual Sales
$51.84 million
Book Value
$12.13 per share


Free Float
Market Cap
$2.84 billion
Not Optionable

Beam Therapeutics Frequently Asked Questions

Should I buy or sell Beam Therapeutics stock right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Beam Therapeutics in the last year. There are currently 2 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" Beam Therapeutics stock.
View analyst ratings for Beam Therapeutics
or view top-rated stocks.

What is Beam Therapeutics' stock price forecast for 2022?

7 brokerages have issued 1 year price targets for Beam Therapeutics' stock. Their BEAM stock forecasts range from $41.00 to $152.00. On average, they expect Beam Therapeutics' share price to reach $110.86 in the next twelve months. This suggests a possible upside of 174.3% from the stock's current price.
View analysts' price targets for Beam Therapeutics
or view top-rated stocks among Wall Street analysts.

How has Beam Therapeutics' stock price performed in 2022?

Beam Therapeutics' stock was trading at $79.69 at the beginning of the year. Since then, BEAM stock has decreased by 49.3% and is now trading at $40.42.
View the best growth stocks for 2022 here

When is Beam Therapeutics' next earnings date?

Beam Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, August 9th 2022.
View our earnings forecast for Beam Therapeutics

How were Beam Therapeutics' earnings last quarter?

Beam Therapeutics Inc. (NASDAQ:BEAM) announced its quarterly earnings results on Monday, May, 9th. The company reported ($1.01) EPS for the quarter, beating analysts' consensus estimates of ($1.10) by $0.09. The company earned $8.40 million during the quarter, compared to analyst estimates of $44.15 million. Beam Therapeutics had a negative net margin of 395.37% and a negative trailing twelve-month return on equity of 28.02%. The company's revenue was up 139900.0% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($3.35) EPS.
View Beam Therapeutics' earnings history

Who are Beam Therapeutics' key executives?

Beam Therapeutics' management team includes the following people:

What is 's approval rating as Beam Therapeutics' CEO?

1 employees have rated Beam Therapeutics CEO on Glassdoor.com. has an approval rating of 100% among Beam Therapeutics' employees. This puts in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Beam Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Beam Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Editas Medicine (EDIT), Cisco Systems (CSCO), Square (SQ), Skyworks Solutions (SWKS), Akoustis Technologies (AKTS), Invitae (NVTA), QUALCOMM (QCOM) and Alector (ALEC).

When did Beam Therapeutics IPO?

(BEAM) raised $101 million in an initial public offering (IPO) on Thursday, February 6th 2020. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan, Jefferies and Barclays served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

What is Beam Therapeutics' stock symbol?

Beam Therapeutics trades on the NASDAQ under the ticker symbol "BEAM."

How do I buy shares of Beam Therapeutics?

Shares of BEAM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Beam Therapeutics' stock price today?

One share of BEAM stock can currently be purchased for approximately $40.42.

How much money does Beam Therapeutics make?

Beam Therapeutics (NASDAQ:BEAM) has a market capitalization of $2.84 billion and generates $51.84 million in revenue each year. The company earns $-370.64 million in net income (profit) each year or ($3.610010) on an earnings per share basis.

How many employees does Beam Therapeutics have?

Beam Therapeutics employs 341 workers across the globe.

How can I contact Beam Therapeutics?

Beam Therapeutics' mailing address is 26 LANDSDOWNE STREET, CAMBRIDGE MA, 02139. The official website for Beam Therapeutics is www.beamtx.com. The company can be reached via phone at 857-327-8775 or via email at [email protected].

This page (NASDAQ:BEAM) was last updated on 6/30/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.